Regranex (becaplermin)
- Region
- 🇪🇺 EU
- Active substance
- becaplermin
- Company
- Janssen-Cilag International NV
- Status
- Withdrawn
- Therapeutic area
- Wound Healing; Skin Ulcer
- EU approval
- Mon 29 Mar 1999
- Application
- EMEA/H/C/000212
- ATC
- D03AX06
- Official record
- www.ema.europa.eu
Indication
Regranex is indicated, in association with other good wound care measures, to promote granulation and thereby the healing of full-thickness, neuropathic, chronic, diabetic ulcers less than or equal to 5 cm2.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Gemesis Refused · BioMimetic Therapeutics Ltd
Follow Regranex
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.